Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The so-called CEO is bent over a barrel (probably lovin' it) as shareholders fingers (digits) continue getting cut off (draining/diluting blood) to raise capital for a cash strapped company on the brink of bankruptcy. Moreau's past immoral acts have finally caught up with him at the worst time in the worst way for shareholders. It's obvious that his words and deeds have yet to carry the day in the eyes of would be newbie investors. It's a silly ass eight million dollar capital raise (in the grand scheme of things) and he's struggling to meet the mark/moment. Everything he touches becomes a long drawn out struggle. How anyone believes Christopher J. Moreau is a real CEO needs their head examined. I wouldn't put that guy in charge of a lemonade stand much less running a public company. My best guess is if long-winded Algernon Pharmaceuticals survives it will be shorted to no end. Sub $1 days are on the horizon. Hold onto your ass. The next cliff will be much steeper than the last.
https://algernonpharma.com/
M$
Test your knowledge of psychedelic drugs... From Charles River Labs Finland, Eureka blog... Hmmm...GLTA...
https://www.criver.com/eureka
Correction: After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Billion shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
Full Stop
Having given the latest F-1/A another look, the Outstanding Shares including the giveaways will increase the outstanding to north of 5 Million Outstanding Shares not including the warrants. If the company survives through all the basement level Phase 1 studies in the pipeline, another massive dilution scheme will take place yet again to move any of them to Phase 2. From there, the question becomes whether or not any of those studies will be powered for stat sig or just another study to determine if they want to move to a real Phase 2 study powered for stat sig. The entire business model is set up for collosal and catastrophic dilution. Moreau will dilute the company back to 100 Million plus shares in no time flat. The pre reverse split shares will literally be worthless. As it would take a Billions upon Billions of dollars market cap to get close to break even. None of their plans are on your side and their timelines are set for them to retire at ripe old ages while draining the public of pennies with pathetic stories. These people have put on a master class of how penny world execs operate in the real world lowlife bowels of the stock market. I've yet to be proven wrong and the numbers don't lie.
Christopher Moreau's goal is to make a life changing difference for shareholders. Anybody remember that tripe spewing out of his mouth in one of those webcast stories?
Newsflash: Moreau wasn't really talking to you. He was talking to the people he loves cherishes and worships. Insiders and anyone else he enjoys getting bent over the rails of their yacht parked along the coastline anywhere in the world. A remote office location for the insiders...yeah I get. It's a lifestyle.
M$
Outstanding: 1,674,868 on June 7, 2022
Monthly 5th Report
https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May.pdf?e4OhHq9hZhO3NgVaBr5QfJ90Mxd5EzNx
Trouble Trouble and more Trouble
The latest dilution plan has now gone from - "This prospectus relates to an underwritten public offering of 1,931,922 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.348"
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm
To - "This prospectus relates to an underwritten public offering of 2,133,333 units (the "Units") of Algernon Pharmaceuticals Inc., each Unit consisting of one Class A Common Share (the "Common Shares") and one warrant (the "Warrants"), based on an assumed offering price per Unit of US$4.125."
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322014238/formf1a.htm
Trouble selling a 4 cents pre reverse split (100 to 1) stock story to family friends Cayman Islands ghost ship investors, etc etc.
It Remains Amateur Hour (+Days, Weeks, Months, Years) @ Algernon Pharmaceuticals Inc.
After the latest fire sale @ Algernon, Christopher Moreau will have effectively taken the company from less than 50 million shares fully diluted to more than 750 Million outstanding shares and north of 1 Million shares fully diluted since his tenure. That's when you factor in both reverse splits of 2 to 1 and 100 to 1.
The dilution moving forward will be at a clip that someone who can't even calculate 2 + 2 will understand. That's if the company ever moves forward >>>
M$
Memorial Day: Remembering Our Fallen Soldiers
Open Question: Go to Page 3 of Algernon Pharmaceuticals - Financial Statements for quarter ended February 28, 2022:
https://webfiles.thecse.com/AlgernonFEB2822FS.pdf?AqxYNIv1.sQXRJQuDMoQZ7yyBewc9eZL
Do you see the type of money being spent on Marketing & Shareholder Communications?
Now look here:
https://www.godaddy.com/domainsearch/find?checkAvail=1&domainToCheck=algernonpharma.com
What I'm saying is the company should have secured this web address from the very beginning. It's the most logical web address for ease of use - less characters is better than more characters. Management should wise up. Someone at yahoo even got livid over it stating there should be legal actions involved. Yeah, that makes a lot of sense. Pay lawyers instead of securing something that can better enhance their overall exposure. Website/email etc etc etc... I'm no expert but I know "algernonpharma.com" looks better than algernonpharmaceuticals.com and the name itself AlgernonPharma versus Algernon Pharmaceuticals. If you go to Algernon's twitter page it says Algernon Pharmaceuticals@AlgernonPharma. It would seem logical that someone thought AlgernonPharma makes sense for Twitter - but not their corporate web address? They don't have to take heed but spending money on a relentless slew of Fly-By-Night web videos is hardly a comparison to rock solid domain name(s).
What the experts say:
https://www.networksolutions.com/blog/establish/domains/why-secure-more-than-one-domain-for-your-business-
Think Clearly:
https://expat-solution-coaching.com/wp-content/uploads/2019/01/its-just-business.jpg
Hav @ It
M$
Outro
Yes, he said $.20 valuation after top line data showed no 'magic wand' for COVID. Neither did Remdesivir, but they sure glommed most Clinical Trials pushing their drug and sold millions of doses around the world with low success compared to their Trial's primary and secondary endpoints and safety issues, IMO. AGN couldnt afford a Phase 3 WITHOUT a 'magic wand', IMO. COVID had vaccines being pushed. AGN needed a new path...IMHFO-.*
( A.U recs on Gld? LOL)
anyway
I took his advice at the time and 'joined the crowd' with many of my long held shares in that obvious rec. Pretty easy call. Bought the pre R/S sale as I feel different about the future of AGN's prospects than you. Maybe I can even buy 100 shares and move the pps 5% like today.
...GLTA...
Rem = Gilead / Wuhan Virologic Institute / coronavirus and batshit soup...
The Outside Man Looking For The Inside Man
My best guess is delusion and dilution will be synonymous to the Algernon story for the foreseeable future. In Christopher Moreau's (CEO) case he takes the cake with Delusions of Grandeur.
As it all relates to this msg board...here we go AGAIN!
Yo tcm55, I get where you're coming from but unfortunately it doesn't mean jack shit as it relates to the COVID-19 study having been a complete flop.
Are you aware of the fact that Interleukin 6 (IL-6) was not...I repeat WAS NOT a Primary or Secondary Outcome (Endpoint) of the COVID-19 study.
https://clinicaltrials.gov/ct2/show/NCT04382924
My Commentary: What you have with Interleukin 6 (IL-6) is after the fact bullshit. If it meant anything of actual significance for the COVID study Moreau wouldn't have finally surrendered to his lame ass narrative about approaching the FDA to move to Phase 3.
Furthermore, Andre Uddin also would have pointed out any statistical significance to his clients that cling to his every word. Thus, it would appear that the only two people who believed in a chance in hell for COVID-19 at Phase 3 is you and Moreau. The overall market responded harshly and rightfully so to Topline data and the stock has never recovered since.
News Release - "Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19."
^Interleukin 6...Guess What...Nobody Cares.
________________
Article Regarding Andre Uddin: In an update to clients on Wednesday, Uddin moved AGN from a “Speculative Buy” to a “Hold,” saying investors should now be focusing on Algernon’s data for its idiopathic pulmonary fibrosis trial, due in the second half of 2021.
Ifenprodil missed the primary endpoint by showing no difference from the control group, while on all-cause mortality, the drug showed a very small non-significant improvement compared to the control group. On oxygenation, 100 per cent of patients with low blood oxygen on Ifenprodil returned to normal oxygen levels at Day 4 compared to Day 9 for patients in the control group, and on time in ICU, patients on the drug spent significantly less time in the ICU than those in the control group.
Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”
“Ifenprodil is in a Phase 2a trial in IPF/chronic cough where results are expected in H2 2021, and AGN’s DMT (a repurposed psychedelic compound) is expected to enter into a Phase 1 trial in stroke in H2 2021,” Uddin wrote. “Investors should re-focus their attention towards the IPF/cough data expected in H2 ’21.”
“Investors should note our AGN valuation is based on the IPF and chronic cough indications of ifenprodil – we are currently keeping our financial assumptions for the two indications intact in our model. We never assumed any revenues from ifenprodil’s COVID-19 indication,” he said.
Along with the new “Hold” rating, Uddin has cut his price target from $0.80 to $0.25, saying the drop is due to a decrease in assumed success rate for Ifenprodil. At the time of publication, the new target represented a projected one-year return of negative 15 per cent.
https://www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
________________
My Commentary:
Uddin's Hold rating of $0.25 is $0.20 USD (20 Cents per share). That's before the very harsh 100 to 1 reverse split. So Uddin's Hold rating would now represent a $20 USD share price at 1.68M Outstanding Shares. That's a Market Cap of $33.6M USD. Also, Uddin expected IPF/Chronic Cough data a year ago! Given the pending dilution and the crazy timeline to data there is no way Uddin still stands by that analysis. However, it appears that Algernon has cozied up to Uddin based on the Corporate Presentation having a banner with Andre Uddin as it's inhouse stock analyst. If anyone is getting word from Uddin about Algernon moving forward it likely would come in the same way the BioPub Dr. KSS looks out for his personal subscribers who pays him money for information. Algernon liked to wrap itself around people whose primary goal is to look out for everyone except common shareholders. Without an inside man you hold a shitty hand.
At the time of Uddin's analysis his projected 1 year return was negative 15 percent (15%).
To date, the return is in fact negative 78 percent (78%).
In reverse split adjustment terms since Uddin's analysis - the stock has dropped from $20 USD to $4.23 USD.
Pending dilution and the NASDAQ uplist will further wipe pre split shares off the map for the foreseeable future.
Ur On The Outside Looking In
As it relates to the Lockout in Australia...it speaks to the border. It does not speak to a Lock-down of it's residents like in China. Don't get the two twisted up in some cockamamie idea that their both one and the same. The bottom-line remains that Australia has a small population pool of potential clinical trial participants. That includes New Zealand where Algernon also remained stymied with dismal enrollment. Yet, the plan for Algernon is to go back to Australia for another slow rolled study of IPF and/or Chronic Cough. How wack is that?! V E R Y
Hav @ it
M$
Hmmm, been closed for 2 years...GLTA...
https://www.reuters.com/world/asia-pacific/australia-fully-reopen-borders-vaccinated-travellers-feb-21-2022-02-07/
https://www.australianclinicaltrials.gov.au/why-conduct-clinical-trial-australia
https://www.australianclinicaltrials.gov.au/
https://www.australia.com/en-us/travel-alerts/coronavirus.html
https://www.worldometers.info/coronavirus/
Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19.
The change in IL-6 levels was one of the biomarkers assessed in this trial.
In a statement, Algernon said: “In the measurement from baseline to day five, IL-6 was reduced in the 20mg treatment arm by 267ng/L, versus 7ng/L in the standard of care arm.”
The results from the Covid-19 study could inform the ongoing Phase II trial of Ifenprodil to treat idiopathic pulmonary fibrosis (IPF) and chronic cough, the company noted.
Encoded by the IL-6 gene, IL-6 functions as a pro-inflammatory cytokine and an anti-inflammatory myokine.
By causing chronic inflammation, IL-6 can lead to fibrosis. In patients with IPF, IL-6 is observed to be higher and its inhibition was found to reduce pulmonary fibrosis in a mouse model.
Earlier this week, Algernon had completed 50% enrolment in the Phase II trial of Ifenprodil for IPF and chronic cough. Changes in IL-6, as well as other fibrosis markers, including C-reactive protein and collagen pro-peptides, will be evaluated in this study.
https://www.pharmaceutical-technology.com/news/algernon-ifenprodil-covid-trial/
TCM55
We know that the company's Ifenprodil focus had modified and that the company"s efforts were mainly COVID in 2020-2021. They got it done under adverse issues. A Phase 3 was not pursued due to costs and vaccinations. The company PR'ed the strong ILK-6 data and obviously has that Trial's data as support for future applications.
IPF/CC was delayed due to COVID but many here hope that Data may finally substantiate Ifenprodil's value for these Lung diseases and to support other Trial applications.
2021 brought licensing of Sub-hallucinogenic micro dose DMT research to pursue along with world class advisors. UK-MHRA applications in 2-2022.
AGN also found and licensed the Stroke research from Dr North (Topotecan) about the SCLC/Pancreatic tumor stuff. Very encouraging, IMO. (personal interest in cancer)
Not bad for a speculative investment, IMO. Buy -Hold - Sell...
I hope you're right about the FDA and implied UK-MHRA approvals of Clinical Trials. I've seen one with DMT and smoking.?.
BUTT... Of course it's not that easy. JMHFO...GLTA...
Just so you know...the FDA will approve of someone's grandma 's recipe for turkey gravy to conduct a study on how fat mice can get by licking it up.
Meanwhile, do you remember Christopher Moreau (CEO) telling the market back in Q4 how EXCITING it was going to be for Algernon Pharmaceuticals in 2022?
It would appear that dredging up old stories suggests one isn't very excited at all. It's gotta be killing Moreau to not be in front of a lens spinning and spewing more stories.
The following web address + email address would be money well spent, but like everything else Moreau does, it'll likely be something management/shareholders will learn the hard way:
https://algernonpharma.com/
After all, all the so-called marketing has been Algernon's biggest quarterly expense. Anybody think they've gotten their monies worth to date?
Expect more of the same...
M$
P.S Anyone seen or heard from the BioPub Boys lately? I'm not a subscriber so I'm curious to know if they're still receiving private updates by the CEO & Company? Maybe it doesn't matter since Dr. KSS remains an insiders advisor (conflict of interest) @ Algernon Pharmaceuticals Inc.
There was a positive response from the FDA for the Topotecan/Ifenprodil combination treatments of SCLC back in Nov 2021.
News due here for AGN's Nasdaq IPO.
More significantly, combination treatments of xenografts in mice with ifenprodil and the chemotherapeutic agent topotecan produced clear additive effects that completely stopped tumor growth. Moreover, the ifenprodil and topotecan combination showed excellent supra-addition or synergy of inhibition for tumors ≤300 mm in size (P=4.7E-4). Combination treatment of memantine with topotecan also showed clear addition but, unlike ifenprodil, no synergy for the doses chosen.
Conclusion: Since topotecan is a drug of choice for treatment of rSCLC, our findings suggest that combining this agent with NMDA receptor blockade using the GluN2B antagonist, ifenprodil, will significantly improve patient outcomes.
https://www.dovepress.com/small-cell-lung-cancer-growth-inhibition-synergism-between-nmda-recept-peer-reviewed-fulltext-article-CPAA
https://www.dovepress.com/small-cell-lung-cancer-growth-inhibition-synergism-between-nmda-recept-peer-reviewed-fulltext-article-CPAA
COVID Breathalyzer
UNT built a breathalyzer that detects COVID. A Frisco company just got FDA approval to put it to work.
How does the device work, exactly?
Verbeck explained that the technology mimics the carbon filter in your refrigerator.
“Carbon is very good at capturing organics and getting them out of your water,” Verbeck said. “So, think of it as exactly the same sort of process. We’ve sort of a carbon substrate — and it is a carbon substrate, but it’s got some extra things in it — that turns to the chemistry that you’re interested in looking at. So, when you’re in a disease state like COVID, your respiratory cells die. They go apoptotic. Which is just a fancy word for cell death.”
When those cells die, Verbeck said, small organic compounds are released that are unique to COVID.
“Those organic molecules are the ones that we’re capturing, and re-releasing back into the instruments,” Verbeck said. “So, that’s called pre-concentrating. So, we just take it, we concentrate onto the substrate like a carbon filter and then we evacuate it, heat it up and off comes the volatile organic compounds that we’re interested in identifying. So, it takes a small amount of air to detect these organic compounds.”
https://dentonrc.com/business/unt-built-a-breathalyzer-that-detects-covid-a-frisco-company-just-got-fda-approval-to/article_a569a515-777c-5ee9-8e40-8fa052e535e3.html
Once upon a time...there was a FAIMS device. A device aimed at detecting diseases or anything else Scientists/Lab Rats wanted to chase after. Then along came Christopher Moreau and the rest of FAIMS story is history.
The End
M$
Sure I/we hope for our fair share, 50% of our company. Taking us to the Nasdaq with a true medical play for DMT, an IPF/CC interim data success with continuity to a next Phase and hooking a big fish for non dilutive financing for the SCLC / pancreatic cancer tumor treatment make a possible NASDAQ Golden Ticket.
The Big Risks we have all supported should have Big Rewards. Could happen with successes.
My dreams are not an investment strategy yet, but like others I have bought and drank the kool-aid. Too late to puke it up now, so I will ride out the trip. A 'long strange trip it's been', too. Almost intolerable waiting. Unimagined circumstances.
CEO CM and the BoD can set the IPO to Reward Long time investors AND employees AND the future PP investors. Of course, it all depends on the level of successes with the current projects, IMO.
Working from their home offices implies needed strict expense controls. They SHOULD be jumping thru all kinds of hoops and wearing out their phones and computers. GOOD. I'm sure they want strong reasons to Reward themselves too. An IPO to the Nasdaq is The Big opportunity for us ALL.
Probably a good time to write CM with opinions, IMO.!.!.!...GLTA...
OAN, Bad form to tantrum. Accept the outcome of the cards and how one played them. JAFO...
+1
Well said. So true.
You actually believe I bare some responsibility for "suppressing" the share price? LMAO. Just wait until the truly professional shorts get ahold of "AGNP" in a Bear Market no less. Certainly you know I have absolutely nothing to do with Christopher Moreau driving the bus over the cliff along with a 20 participant data readout still awaiting closure after 2 years.
Final Data will likely extend the unBEARable drama another 6 months. 2.5 years to complete a 6 months or less "study" had it been conducted in North America. Bellus Health had more than 10 times the participants and got it done in less than 1 year. It's no pure comparison by any stretch of the imagination but that won't stop Mush Mouth Moreau from trying to make it so.
Any thought of what the share price might be now had Algernon gotten positive Chronic Cough data back in 2020 or Q1 2022? Data that could have gone head up with Bellus Health. My best guess is AGNPF would be north of $1 without having orchestrated a punishing 100:1 reverse split. The momentum and everything else got sucked straight into a black hole in Australia.
Did I mention the Minds of Management is going back to that same lame ass Phase 2 (a? b? b3?) "tax write-off' scenario in Australia for it's next Phase 2 (a? b? b3?) IPF/Chronic Cough study? Incredible how they've traveled full circle to expose themselves (the emperors has no clothes) as true dilution machine whores.
Whores : to pursue an unworthy desire.
In any event, 3.5 years into the Black Hole Annals of Algernon Pharmaceuticals (The Shit Stinks)...
I've shaved many shares along the way since holding well north of a million shares of this Shit Show Stock. Whether or not I've made any money along the way is irrelevant. What's relevant is Facts over Fiction - Reality over Virtual Reality - Activism over Appeasement. I have not changed since Day 1 (A1). It remains my opinion that your analogy of where things stand is kooky at best.
To anyone who finds themselves falling down the rabbit hole of stories told by the CEO... Beware the Black Hole.
M$
TCM55, Thank you!!
Luckly we all have a concerned citizen repeatably posting the all doom scenarios for ages to help suppress the pps while complaining about loss of it's moneyshot and blaming other's for a 4 year+ hold thru the company's struggles to produce a winning ticket. Very few have traded to profits here so far, some have mitigated the damage though. Speculative investments are that way. Duh.
MY Nasdaq 10M OS concept includes a 3 for 1 to longs. Duh...
I wrote and complained about the value loss of long time shareholders and suggested the possibility of rewarding longs IF successes warrant it in the IPO. A higher MC could happen before the IPO, enabling 'stuff'.
Bad news and we all lose. Good news and long time shareholders should win too, not just the newest PP holders. IMO.
ALL shareholders can pen emails with their expectations or write floundering epitaphs and excessive hind sighted whiney posts on message boards. Buy or Hold or Sell
BTW, name a stock where an IPO does not have bonuses/stock for management, etc.
...GLTA...
No worries. The tcm here couldn't possibly be the same tcm there. Got it! However, both tcm's have come up with a random number of 10M Outstanding Shares (OS) issued - from doubling the current OS - to the pending OS (3.5M) - to instead QUINTUPLING (10M) the current OS - as some sort of loyalty reward for shareholders. I think it's the kookiest thing I've read yet about the Nasdaq uplist - to include bonuses for management (What the fuuu)?
Sir, I applied simple math in my previous post as one overwhelmingly EZ to understand example of why that idea would help absolutely no one. I will leave it to others to come to their own conclusions. Furthermore, I believe everyone who reads this msg board already knows how to navigate their way to other Algernon message boards to read and/or opine. You make it seem as if the internet itself is a newly discovered phenomenon.
Just to add further clarity here as if it's necessary:
tcm - "...will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds."
What I gather is YOU STILL do not understand that the IPO is etched in stone to the point the Market Cap is irrelevant to raising further capital in the immediate future. The 8.4M USD is the number they will come away with (actually it's 7.4M USD).
Now go back and look at the SEC F1/A filing to see how much of that money is to be allocated for Chronic Cough. It shows 500k is going towards ANOTHER Phase 2 trial in Australia. Not only that, it's not a standalone Chronic Cough study. It's including IFP which Moron Moreau himself said is a bad idea.
Yet...here they are again doing the same thing over again in a country that he knows will slow roll enrollment. Algernon Pharmaceuticals is being ran by natural born losers.
Expect another capital raise in 2023 if any of the Phase 1's come away with any data subject to further pursuit. Given "safety" is the only hurdle at Phase 1, surely you can expect "AGNP" will soon become a shorts Dream Dilution Machine on steroids for years to come.
Someone ask Beer Buddy when does he expect a Phase 2 Chronic Cough study to start in Australia - and when does he expect it to end. Then add at least 1 year to whatever answer spews out of his mouth.
Note that Bellus Health ran their USA standalone Phase 2 Chronic Cough clinical trial in less than one year from beginning to Final Data Readout. Remember that everytime Moreau mentions them as a pure comparison.
Mark this post.
M$
Was there more to the discussion or a response? When was this all written? Why post it here? ...
.I think that the announcement of an approved Phase 1 Clinical Trial by the UK-MHRA for Stroke using micro-dosed DMT, ALONG with other news that is due, will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds.
All proportionate to the levels of success...IMO.
Maybe even reward long term shareholders.?. Bonuses for sure.
(3x1.7M) = 5.1M +5.6M (+) = about 11M OS?
Just another message board poster's opinion.
Was there more to the discussion or a response? When was this all this written? Why post it here? ...
.I think that the announcement of an approved Phase 1 Clinical Trial by the UK-MHRA for Stroke using micro-dosed DMT, ALONG with other news that is due, will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds.
All proportionate to the levels of success...IMO.
Maybe even reward long term shareholders.?. Bonuses for sure.
(3x1.7M) = 5.1M +5.6M (+) = about 11M OS?
Just another message board poster's opinion.
Re: Discussion from AGNPF Yahoo msg board
@tcmoiba That's absolutely nuts! You are advocating for yet more dilution where $30 is already the break even point for pre split shares. Absolutely bonkers idea. The stock will already be luck to trade above $3 once uplisted. Do simple math. They are selling more than half the company for $8 million. That means the current market cap of $6 million to $7 millions is what the market believes the company is worth. Adding $8 million to run clinical trials doesn't increase the overall value at Phase 1. So here's more simple math ... Take the current market cap of 6 million and add the 8 million capital raise. That puts you at 14 million market cap. Divide the 14 million by 3.5 million shares outstanding. That leaves you with a share price of $4 USD. Now go look at XRTX where they recently uplisted and Algernon's CEO compares Algernon's uplist to. XRTX is trading at sub $2 per share at less than 20 million market cap and they are already conducting clinical trials. That's where Algernon is headed on the Nasdaq. This stock is prime for getting the #$%$ shorted out if it like never before in penny world. Live and Learn the Hard Way.
__________________________
IMO, Christopher Moreau can remain on his webcast crusade but it's not going to do a damn thing for the share price at Phase 1. Surely, he will be in a - forget about the past - mode and barrel ahead head first towards another cliff.
The best thing they could do with that 8 million is doend it all on a standalone Chronic Cough clinical trial powered for statistical significance and conducted in North America That is Algernon's best and likely OBLY true shot at getting shareholders back to even @ $30 per share. Will that happen...of course not. They are too busy diluting the company for pie in the sky BS and flavor of the month angles. Before it was covid...now it's psychedelics. Once they drive the bus over the next cliff they will be onto whatever else becomes a hot topic. Meanwhile, Bellus Health is rolling up their sleeves and doing real world pharma deals not virtual reality management shit - phoning it in.
M$
Sad the microdose DMT UK MHRA clinical trial application approvals have taken so long. The pps reflects the delay as does the add-on to the initial prospectus. With these delays in getting approvals and the probable extra documentations needed, AGNPF is still spending to get it done. Sucks to be a long time supporter/shareholder right now. Double down or fold.?.
There is this nugget of 'newspeak' I had not seen before implying NASDAQ listing approval....
" We have applied to have our Common Shares listed on the Nasdaq Capital Market under the symbol "AGNP" and recently received approval to list our Common Shares on Nasdaq Capital Market. The successful listing of our Common Shares and Warrants on the Nasdaq Capital Market is a condition of this offering. We do not intend to apply for listing of the Pre-Funded Warrants on the Nasdaq Capital Market."
...GLTA...
Dilution to make your head spin. Long shares are about to get raked over the coals beyond the 2 to 1 and 100 to 1 reverse splits.
Offering Price lowered and Shares/Warrants increased. Additional 500,000 Shares + 500,000 Warrants for public offering and underwriters. 8M Capital Raise to 8.4M Capital Raise.
Total Shares + Warrants up for grabs - 4,363,984
Current Outstanding Shares - 1,674,868
Current Warrants - 527,770
Outstanding Shares after public offering - 3,856,860
Warrants after public offering - 2,709,762
Fully Diluted Shares - 6,566,622
Form F1/A
Amendment #4 - Filed April 25 2022
1,684,210 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share
1,684,210 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share
We will sell these Units at a public offering price of US$4.75 per Unit.
Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322010694/formf1a.htm
Form F1/A
Amendment #5 - Filed May 9 2022
In December 2021, we became a remote-first company. Accordingly, we do not currently maintain a headquarters.
1,931,922 Units, each Unit Consisting of One Common Share and one Warrant to Purchase one Common Share
1,931,922 Pre-funded Units, each Pre-funded Unit Consisting of one Pre-Funded Warrant to Purchase one Common Share and one Warrant to Purchase one Common Share
...based on an assumed offering price per Unit of US$4.348, the last reported price of our Common Shares as reported on the OTC Market Group Inc.'s Venture Market (the "OTCQB") on May 5, 2022. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of 110% of the price of the Units in this offering
We have granted the underwriters a 45-day option (commencing from the date of this Prospectus) to purchase up to an additional 289,788 Common Shares and/or up to an additional 289,788 Warrants at the public offering price per Common Share and per Warrant respectively
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011852/formf1a.htm
FWP (Prospectus) - Filed May 10 2022
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322011950/formfwp.htm
A free writing prospectus (FWP) is a written communication regarding securities being publicly offered disseminated by the issuer during the waiting period of an initial public offering (IPO) that discloses information that would not be included in the registration statement.
https://www.law.cornell.edu › wex
M$ comment:
Longs holding pre-split shares will need a Market Cap of $200M USD to break even. Basically dead money here for the foreseeable future. As I see nothing in the pipeline to get to that valuation prior to a standalone clinical trial for Chronic Cough with stat SIG results better than Bellus Health. Meanwhile, the walls around Algernon appear to be on fire but for the fact the company no longer has a corporate office. Pure insanity with Moreau's prior BS decisions and timelines driving the company over every cliff imaginable. Moreau stated his goal was to provide shareholders with "Life-changing" returns on their investment. Uhh ok. In what lifetime - this one or the next? A standalone Chronic Cough Phase 3 clinical trial should already be underway. It's the best shot at success purchased by shareholders back in 2018. Christopher Moreau is unequivocally the absolute worst "CEO" ever.
Stay tuned
https://algernonpharma.com/
At this snail's pace to uplist, I wouldn't be surprised if bonehead scrapped the whole story and simply did another CSE private placement for around $2 per share - 4 million shares + 4 million warrants. Run it all to hell at 10 million shares outstanding after warrants exercise at $2.75 per share. I put nothing past the evil that men do.
Surely, no one's listening to/taking seriously the CEO. Thus, I'd love to hear a single word ever come out of the mouth of the Chairman Of The Board regarding Algernon Pharma-ceuticals future outlook.
Meanwhile, someone please tell Beer Buddy I said hell/low.
M$
Outstanding: 1,674,868 on May 9, 2022
Monthly 5th Report
https://webfiles.thecse.com/4_-_Algernon_-_CSE_Form_7_-_April.pdf?PufoA7Ex99ESx52RtbUjr0IciPwL2Rqs
On Tomorrow: Happy Mother's Day To All Mother's In This Life & The Afterlife
Were the Ifenprodil COVID Clinical Trial results BETTER than the Pfizer pill Paxlovid? Safety?
Big Pharma monie$.?. Does this infer strong results for the Ifenprodil IPF/CC study?
...GLTA...
https://www.investopedia.com/pfizer-covid-treatment-pill-falls-short-5271094
https://www.deseret.com/coronavirus/2021/12/27/22855500/pfizer-covid-pill-covid-19-symptoms-risky-side-effects?msclkid=b03957f8cd5811ec92bafc8932c10d79
Common Sense 101
Facts are not a hard thing to come by if one is seriously interested in finding facts versus filtered fiction. The fact of the matter is you never go to clinicaltrials.gov to follow the latest information coming directly out of the CEO's mouth. You go to the corporate website.
News Release:
...The Company is projecting a data readout in calendar Q2, 2022.
“We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
https://www.globenewswire.com/news-release/2022/02/04/2379200/0/en/Algernon-Pharmaceuticals-Announces-Completion-of-Enrollment-in-its-Phase-2-Study-of-Ifenprodil-for-IPF-and-Chronic-Cough.html
As I stated, management missed yet another quarter just like the pipeline illustration as well.
See IPF/CC "Data - Q2 2022"
Expect Final Data no earlier than Q4 2022.
Just in time for your Annual (Anal) lump of coal stocking stuffer.
CJM IS The Grinch Who Steals Christmas
Just facts,
M$
Postscript
For arguments sake, I read 55's post at Yahoo. He illustrated an "update" regarding the IPF/CC clinical trial. The update is dated March 2022. Now look at the date of the above news release. What would have materially changed from February to March that would suggest Moreau didn't know when data would be available to the public for another quarter (Q2 now Q3)? The bottom line is management missed another quarter to report data from a clinical study that's been fundamentally flawed from the outset.
4D Outro
Think Outside The Box
@ algernonpharma.com
Looks like they have made their target dates. Just confirming the completion and actual top line data date.?.
Primary Completion: May 2022 [Anticipated]
Study Completion: June 2022 [Anticipated]
https://clinicaltrials.gov/ct2/history/NCT04318704?A=1&B=9&C=Side-by-Side#StudyPageTop
Australia and NZ have had serious COVID issues even after closing their countries initially in 2020. For a while Australia was one of the lowest infected countries. Now it is one of the worst.
Sad for all Ausies and that it affected our CT too, making it take this long.
Sure hope the wait proves worthwhile.
Australia Total 6,130,748 New cases +54,868 hospitalized 7,423
https://www.worldometers.info/coronavirus/
Play The Card You've Just Been Dealt
Management misses yet another Quarter in releasing data.
“We are pleased to be coming closer to this value inflection point in our Phase 2 clinical trial for IPF and chronic cough, both debilitating conditions with limited treatment options,” said Christopher J. Moreau, CEO of Algernon.
Value Inflection Point? ROTFLMAO. When have we heard Moreau say that line before - the COVID-19 Topline & Final Data flops? Yeah, ok. Where's Andre Uddin when you need a 20 Cents per share ($2 post "consolidation") analysis of the data? You can now expect a nothing burger final data readout not in Q2 or Q3 but in Q4 2022.
M$
Last Patient Treated in Phase 2 Study of IPF and Chronic Cough
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/145/algernon-pharmaceuticals-announces-last-patient-treated-in
Yes, an IPF/CC Phase 2 in the US is a good idea. Non dilutive funding for Cancer tumor treatments is possible too for Ifenprodil.
Yes, I think alot of interest will be seen with the Micro dose DMT Clinical Trial approval from UK MHRA.
Everywhere I play there are no redo hands. Bet on the next hand or leave the table...
...GLTA...
55 - "...A Big Splash entering the NASDAQ"
Yeah, it's no longer about Christopher Moreau's "Everybody Wants In At Phase 2."
Now it's - Everybody Wants In At Phase 1.
Is Moreau's infamous quote suppose to be a clever idiom or merely a line made up for idiots?
After dilution the Market Cap will need to be well north of $150M USD @ $30 per share to break even on the pre-consolidation of shares (100 to 1 Reverse Split) - lest you ever forget.
Big Splash
M$
CSE + OTC = Bipolar Market Makers
BLOZF + AGNPF = Team Cobra/Clown Team
algernonpharmaceuticals.com + algernonpharma.com = Smart Business
NASDAQ Uplist + Standalone Chronic Cough Clinical Trial In USA = only real chance of success for common shareholders
Bellus Health + Algernon Pharmaceuticals = Winners versus Losers
Carry on...
https://investorshub.advfn.com/uimage/uploads/2022/5/3/vxfvhistockphoto-185919303-612x612.jpg
M$
Someone has made a claimed smart move and expressed their opinions, so it can now move on, or wait and chase or bragg how smart and right it's been, or poot themself IF getting UK-MHRA approvals (or other pending news) jumps this speculative investment and it then makes A Big Splash entering the NASDAQ. JMHFO...GLTA...
Anyone else claiming to be confused?
Shareholders with real money (not lunch money) that vanished like magic under the Big Top certainly are not confused. The Clown Team has a remarkable ability to waste money and time. Thus, I'll remind any confused shareholders the very last so-called clinical trial @ AlgernonPharma (AP) was launched back in July of 2020 and still pending a 20 patient data readout.
The 1st truly powered for stat sig "Everybody Wants In @ Phase 2" clinical trial will likely not conclude until 2025 or 2026. In such time, I expect AP to follow the same path as Xortx. Moreau had already signalled he plans to follow in Xortx footsteps. Moreau hired their former CEO (sheesh). Look at Xortx pathetic performance since uplisting to Nasdaq - Market Cap: 17M USD
Yet another losing strategy @ AlgernonPharma
M$
very confusing post.?.
MMND and CMPS are both doing Trials for the mental health uses of psychedelics. CMPS's recent trial was single large dose. I personally wouldn't support that level of a 'high' for anyone and like another company's MOU much better.
They both had larger MCs but are still about $300-400M now. Both have $0 revs.
AGN has followed the different path of the neuroplasticity effects of micro dosed DMT.
Seems a Big difference in the MOUs / applications of psychedelics with different patient groups.
Dr Nutt has significant insights for Both, IMO.
An occasional small dose of Shrooms DOES mitigate some of the side effects of chemo and mental stress, IMO. True hallucinogenic experiences should be left to the young and dumb, IMO...GLTA...
My point about Nutt and management stands without trying to confuse the matter here in fly over country.
As always ...I offer real world due diligence. I've never been a stowaway barking from the cargo area.
I'm guessing flyover country has finally moved on from the ridiculous baggage claims about waiting for this that or the other tests to reap some kind of benefit before a capital raise.
However, I assume it will always be some kind of testing this that or the other thrown in the mix to make excuses for managements non-stop failures to execute.
Simple sh!t to understand in pennyland ain't complicated. Which is why Algernon remains stuck on the runway.
Geez Us...I'm tired of holding passengers hands.
M$
CMPS does depression disorders while AGN is testing neuroplasticity related to Stroke. Dr Nutt would seem to be able to advise both companies about DMT without issues, IMO. He IS one of the most respected voices in this field.
IF AGN finally gets positive news about their UKMHRA clinical trials' applications it may still make that conference, AS the STAR.
BTW, I agree that there are positive effects from 'shrooms for depression and ptsd. Might even help cure cancer.
...GLTA...
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |